Mito BioPharma is a biopharmaceutical company that focuses on targeting mitochondria and cellular metabolism modulation for the development of therapeutics. It uses a proprietary, small molecule-based technology and lead compounds that modulate mitochondrial functions. The company centers on liver-based diseases, in particular, NASH (non-alcoholic steatohepatitis) and type 2 diabetes.